- Home
- CRI vs KNSA Comparison
CRI vs KNSA Comparison
Compare CRI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRI
- KNSA
- Stock Information
- Founded
- CRI 1865
- KNSA 2015
- Country
- CRI United States
- KNSA United Kingdom
- Employees
- CRI N/A
- KNSA N/A
- Industry
- CRI Apparel
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CRI Consumer Discretionary
- KNSA Health Care
- Exchange
- CRI Nasdaq
- KNSA Nasdaq
- Market Cap
- CRI 1.9B
- KNSA 1.7B
- IPO Year
- CRI 2003
- KNSA 2018
- Fundamental
- Price
- CRI $54.00
- KNSA $21.28
- Analyst Decision
- CRI Hold
- KNSA Strong Buy
- Analyst Count
- CRI 6
- KNSA 5
- Target Price
- CRI $67.67
- KNSA $36.60
- AVG Volume (30 Days)
- CRI 1.4M
- KNSA 365.0K
- Earning Date
- CRI 10-25-2024
- KNSA 10-29-2024
- Dividend Yield
- CRI 5.93%
- KNSA N/A
- EPS Growth
- CRI 15.51
- KNSA N/A
- EPS
- CRI 6.33
- KNSA N/A
- Revenue
- CRI $2,842,254,000.00
- KNSA $384,098,000.00
- Revenue This Year
- CRI N/A
- KNSA $60.05
- Revenue Next Year
- CRI N/A
- KNSA $36.32
- P/E Ratio
- CRI $8.53
- KNSA N/A
- Revenue Growth
- CRI N/A
- KNSA 54.41
- 52 Week Low
- CRI $50.27
- KNSA $15.52
- 52 Week High
- CRI $88.03
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- CRI 43.82
- KNSA 36.27
- Support Level
- CRI $50.55
- KNSA $20.41
- Resistance Level
- CRI $54.63
- KNSA $21.55
- Average True Range (ATR)
- CRI 1.67
- KNSA 0.84
- MACD
- CRI 0.41
- KNSA -0.10
- Stochastic Oscillator
- CRI 85.33
- KNSA 28.02
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of Carter's sales are in the U.S. and through Carter's brand. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.